Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib

Nakagawa, 2003, Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors, Ann. Oncol., 14, 922, 10.1093/annonc/mdg250 Ranson, 2002, ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial, J. Clin. Oncol., 20, 2240, 10.1200/JCO.2002.10.112 Herbst, 2002, Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial, J. Clin. Oncol., 20, 3815, 10.1200/JCO.2002.03.038 Baselga, 2002, Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types, J. Clin. Oncol., 20, 4292, 10.1200/JCO.2002.03.100 Fukuoka, 2003, A multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial), J. Clin. Oncol., 21, 2237, 10.1200/JCO.2003.10.038 Kris, 2003, Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial, JAMA, 290, 2149, 10.1001/jama.290.16.2149 Inoue, 2003, Severe acute interstitial pneumonia and gefitinib, Lancet, 361, 137, 10.1016/S0140-6736(03)12190-3 AstraZeneca Japan. Final report on interstitial lung disease (ILD) related to gefitinib (Iressa® Tablet 250) by Iressa Expert Committee; 26 March 2003. Shah, 2003, Bronchioloalveolar histology and smoking history predict response to gefitinib [abstract 2524], Proc. Am. Soc. Clin. Oncol., 22, 628 Johnson, 2003, Gefitinib in recurrent non-small-cell lung cancer: An IDEAL trial?, J. Clin. Oncol., 21, 2227, 10.1200/JCO.2003.04.001 Bailey R, Kris MG, Wolf M, et al. Tumor epidermal growth factor receptor (EGFR) expression levels does not predict for response in patients receiving gefitinib (“Iressa”, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res. 2003;1362. Arteaga, 2001, The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia, J. Clin., Oncol.19, 32s Franklin, 2002, Epidermal growth factor receptor family in lung cancer and premalignancy, Semin. Oncol., 29, 3, 10.1053/sonc.2002.31520 Moasser, 2001, The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells, Cancer Res., 61, 7184 Moulder, 2001, Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/Neu (erb-2)- overexpressing breast cancer cells in vitro and in vivo, Cancer Res., 61, 8887 Anido, 2003, ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpression breast cancer cells, Clin. Cancer Res., 9, 1274 Hirsch, 2002, Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas, Br. J. Cancer., 86, 1449, 10.1038/sj.bjc.6600286 Siegfried, 2001, Women and lung cancer: does oestrogen play a role?, Lancet Oncol., 2, 506, 10.1016/S1470-2045(01)00457-0 Hom, 1998, Uterine and vaginal organ growth requires epidermal growth factor receptor signaling from stroma, Endocrinology, 139, 913, 10.1210/en.139.3.913 Husgafvel-Pursiainen, 1996, Cigarette smoking and p53 mutations in lung cancer and bladder cancer, Environ. Health Perspect., 104, 553, 10.1289/ehp.96104s3553 Ahrendt, 2001, Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung, Cancer, 92, 1525, 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H Cohen, 2003, Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck, J. Clin. Oncol., 21, 1980, 10.1200/JCO.2003.10.051 Clark, 2003, Rash severity is predictive of increased survival with erlotinib HCl [abstract 786], Proc. Am. Soc. Clin. Oncol., 22, 196